Remove

Pages,Columns,Lines where

Under the Paperwork Reduction Act of 1995, no persons are d to a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10096124	
	Filing Date		2006-05-31	
	First Named Inventor Philip		ppe TARDIEU	
	Art Unit		TBA	
	Examiner Name	TBA		
	Attorney Docket Number		50304/126001	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	of cited Decument		s,Columns,Lines where ant Passages or Relevant es Appear			
	1	4955811		1990-09-11	Lazzara et al.					
	2	4988297		1991-01-29	Lazzara et al.					
	3	5564925		1996-10-15	Shampanier e	xtal.				
If you wis	h to ac	dd additional U.S. Pater	nt citatio	n information	please click the	Add button.		Add		
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Publication Name of Patentee or Applicant		Releva		Lines where ges or Relev	
	1									
If you wis	h to a	dd additional U.S. Publi:	shed Ap	plication cita	ion information	please click the Ad	d button	Add		
If you wis	h to a	td additional U.S. Publis		·	tion information		d button	Add		
If you wis	_	dd additional U.S. Publis Foreign Document Number <sup>3</sup>		FOREIGN P	ATENT DOCUM		e or	Remove Pages,Colu	or Relevant	Ts

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596124		
Filing Date		2006-05-31		
First Named Inventor Philip		pe TARDIEU		
Art Unit		TBA		
Examiner Name TBA				
AU DILINII		E02041420004		

					1002 00 10			
	3	WO 97/10770 A	wo		1997-03-27			
	4	EPO 640 322	EP		1995-03-01			
If you wis	h to a	dd additional Foreign F	atent Document	citation	information pl	ease click the Add butto		
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		mal, serial, symp	osium,	catalog, etc), o	the article (when approp late, pages(s), volume-is		Ţ5
	1	International Search Report (PCT/EP2004/013435)						
	2 Written Cymion of the International Searching Authority (PCT/EP2004/013435)							
3 Response to Written Cylinion (PCT/EP2004/013435) filed July 20, 2005.								
	4	International Preliminary Report on Patentability (PCT/EP2004013435) mailed March 16, 2006.						
If you wis	h to a	dd additional non-pate	nt literature docu	ment cit	ation informati	on please click the Add	outton Add	
			EX	AMINE	R SIGNATUR	E		
Examiner	Signa	nture				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applica	ation Number		10596124	
	Filing Date		2006-05-31	
	First Named Inventor Philip		pe TARDIEU	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Un	Art Unit		TBA	
	ner Name	TBA		
Attorne	ey Docket Numb	er	50304/126001	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10596124			
Filing Date		2006-05-31			
First Named Inventor Philip		pe TARDIEU			
Art Unit		тва			
Examiner Name TBA					
Attorney Docket Number		50304/126001			

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 an	1 1.98 to make the appropriate selection(s):
---------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

- ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/James D. DeCamp/	Date (YYYY-MM-DD)	2006-10-19
Name/Print	James D. DeCamp	Registration Number	43,580

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comment of Office, and Superiment of Commence, P. 0. 8th 44D, Alexandrin, V.S. 2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.